Palisade Bio reports Phase 1a results for PALI-2108

Palisade Bio (PALI) announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D inhibitor being developed for fibrostenotic Crohn’s disease, FSCD, and moderate to severe ulcerative colitis. The Phase 1 program, which included single ascending dose, multiple ascending dose, and cross-over food effect studies in adult healthy volunteers, as well as a small cohort of UC patients, successfully met its primary endpoints of safety, tolerability, and pharmacokinetics. The data support progression into Phase 2 development.